Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors
Edward Sausville, Patricia LoRusso, Michael Carducci, Judith Carter, Mary F. Quinn, Lisa Malburg, Nilofer Azad, David Cosgrove, Richard Knight, Peter Barker, Sonya Zabludoff, Felix Agbo, Patricia Oakes, Adrian Senderowicz
Dive into the research topics of 'Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors'. Together they form a unique fingerprint.